Ustekinumab: differential use in psoriasis

Differential response of chronic plaque psoriasis to briakinumab vs. ustekinumab.

Emerging dermatological and systemic applications of ustekinumab: beyond its clinical use in psoriasis

Correspondence: Shailendra Kapoor 2300 E Cary Street, Richmond, VA 23223, USA Email [email protected] I read with great interest the paper by Uhlenhake and Mehregan in a recent issue of your journal. The article is highly thought-provoking. Interestingly, the past few years have seen increased use of ustekinumab in clinical applications other than psoriasis. For instance, ustekinumab i...

Economic Burden Can Be the Major Determining Factor Resulting in Short-Term Intermittent and Repetitive Ustekinumab Treatment for Moderate-to-Severe Psoriasis

Background The continuous use of biologic agents in the treatment of psoriasis has been reported to result in successful and sustained therapeutic effects and safety. However, some patients choose intermittent and repetitive treatment. Objective To determine the factors for selecting intermittent and repetitive ustekinumab treatment for the management of psoriasis. Methods From January 2011...

The MARCOPOLO Study of Ustekinumab Utilization and Efficacy in a Real-World Setting: Treatment of Patients with Plaque Psoriasis in Asia-Pacific Countries

BACKGROUND Ustekinumab is a fully human monoclonal antibody approved for the treatment of chronic moderate-to-severe plaque psoriasis in adults. However, factors including efficacy, tolerability, ease of use, and cost burden may affect ustekinumab utilization. Noncompliance may, in turn, affect treatment response. OBJECTIVE To evaluate ustekinumab utilization in the real-world setting in Asia...

Atopic dermatitis exacerbated with ustekinumab in a psoriatic patient with childhood history of atopy.

Ustekinumab is a biological agent that is currently approved for the treatment of moderate to severe plaque psoriasis. It is a monoclonal antibody that binds the p40 subunit of IL-12 and IL-23 to limit the progression of the Th1 and Th17 inflammatory immune responses. Recently, it has been suggested that ustekinumab could represent a potential treatment for atopic dermatitis (AD).1e3 However, i...